Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Search

Page Path
HOME > Search
2 "Smoking"
Filter
Filter
Article category
Keywords
More +
Publication year
Authors
More +
Original Article
Colorectal neoplasia
Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
Intest Res 2023;21(4):510-517.   Published online May 31, 2023
DOI: https://doi.org/10.5217/ir.2022.00139
AbstractAbstract PDFPubReaderePub
Background/Aims
Patients with more than 10 cumulative polyps might involve a greater genetic risk of colorectal neoplasia development. However, few studies have investigated the risk factors of polyposis recurrence and development of advanced neoplasms among patients with non-hereditary colorectal polyposis.
Methods
This study included patients (n=855) with 10 or more cumulative polyps diagnosed at Severance Hospital from January 2012 to September 2021. Patients with known genetic mutations related to polyposis, known hereditary polyposis syndromes, insufficient information, total colectomy, and less than 3 years of follow-up were excluded. Finally, 169 patients were included for analysis. We collected clinical data, including colonoscopy surveillance results, and performed Cox regression analyses of risk factors for polyposis recurrence and advanced neoplasm development.
Results
The 169 patients were predominantly male (84.02%), with a mean age of 64.19±9.92 years. The mean number of adenomas on index colonoscopy was 15.33±8.47. Multivariable analysis revealed history of cancer except colon cancer (hazard ratio [HR], 2.23; 95% confidence interval [CI], 1.23–4.01), current smoking (HR, 2.39; 95% CI, 1.17–4.87), and detection of many polyps (≥15) on index colonoscopy (HR, 2.05; 95% CI, 1.21–3.50) were significant risk factors for recurrence of polyposis. We found no statistically significant risk factors for advanced neoplasm development during surveillance among our cohort.
Conclusions
The presence of many polyps (≥15) on index colonoscopy, history of cancer except colon cancer, and current smoking state were significant risk factors for polyposis recurrence among patients with non-hereditary colorectal polyposis.

Citations

Citations to this article as recorded by  
  • Prognosis of Korean patients with familial adenomatous polyposis who did not undergo colectomy: a retrospective study
    Min Kwan Kwon, Jin Hee Noh, Ji Yong Ahn, Woochang Lee, Seok-Byung Lim, Yong Sang Hong, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Dong-Hoon Yang
    Clinical Endoscopy.2026; 59(2): 254.     CrossRef
  • Influence of Lifestyles on Polyp Burden and Cancer Development in Hereditary Colorectal Cancer Syndromes
    Hye Kyung Hyun, Ji Soo Park, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
    Journal of Gastroenterology and Hepatology.2025; 40(2): 433.     CrossRef
  • Identification of Genetic Factors Related With Nonhereditary Colorectal Polyposis and Its Recurrence Through Genome‐Wide Association Study
    Jung Hyun Ji, Su Hyun Lee, Chan Il Jeon, Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Sun Ha Jee, Tae Il Kim
    Journal of Gastroenterology and Hepatology.2025; 40(2): 482.     CrossRef
  • Machine learning in colorectal polyp surveillance: A paradigm shift in post-endoscopic mucosal resection follow-up
    Vasily Isakov
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Screening and surveillance for hereditary colorectal cancer
    Hee Man Kim, Tae Il Kim
    Intestinal Research.2024; 22(2): 119.     CrossRef
  • 5,429 View
  • 318 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Review
IBD
The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease
Steven Nicolaides, Abhinav Vasudevan, Tony Long, Daniel van Langenberg
Intest Res 2021;19(2):158-170.   Published online October 13, 2020
DOI: https://doi.org/10.5217/ir.2020.00008
AbstractAbstract PDFPubReaderePub
Smoking significantly increases the risk of developing and worsens Crohn’s disease (CD), yet protects against the development and reduces the severity of ulcerative colitis. It is less clear whether smoking impacts the efficacy of therapeutics in inflammatory bowel disease (IBD). We review the literature regarding the relationship between smoking and the efficacy of medical and surgical therapy in IBD. Smoking is associated with alterations in thiopurine metabolism and may affect time to disease relapse. The outcomes of anti-tumor necrosis factor therapy in active smokers appear neutral with data lacking for newer biologics. Smoking increases the risk of postoperative recurrence in those requiring resection for CD, likely attributable to perturbations of the gut microbiota although further implications of these for disease onset/progression and treatment efficacy remain unclear. Multiple lifestyle and psychosocial confounders are likely under-recognized cofactors in the association between smoking and IBD. Despite the widely promulgated risks associated with cigarette smoking in CD, more incisive data are required to further elucidate the actual relationship between smoking and disease pathways, while accounting for the several negative cofactors prevalent in smokers which cast uncertainty on the magnitude of the direct effect of smoking on disease pathophysiology and the efficacy of therapy.

Citations

Citations to this article as recorded by  
  • Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives
    Xiaona Yang, Hong Guo, Min Zou
    Molecular Biomedicine.2026;[Epub]     CrossRef
  • DAMP-ing IBD: Extinguish the Fire and Prevent Smoldering
    Oliver Sandys, Pieter C. F. Stokkers, Anje A. te Velde
    Digestive Diseases and Sciences.2025; 70(1): 49.     CrossRef
  • The Effects of Combustible Cigarettes and Electronic Nicotine Delivery Systems on Immune Cell-Driven Inflammation and Mucosal Healing in Ulcerative Colitis
    Nikolina Kastratovic, Vladimir Markovic, Aleksandar Arsenijevic, Ana Volarevic, Natasa Zdravkovic, Marija Zdravkovic, Marija Brankovic, Tijana Gmizic, Carl Randall Harrell, Vladimir Jakovljevic, Valentin Djonov, Vladislav Volarevic
    Nicotine and Tobacco Research.2025; 27(3): 542.     CrossRef
  • Smoking Experience before Adulthood Is Associated with an Increased Risk of Developing Ulcerative Colitis in Adult Ex-Smokers
    Yu Kyung Jun, Bongseong Kim, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Kyungdo Han, Hyuk Yoon
    Yonsei Medical Journal.2025; 66(1): 9.     CrossRef
  • Recurrence rates after strictureplasty for small bowel Crohn's disease remain high in the era of biologics
    A. Nasasra, T. E. M. Morrison, A. Luberto, M. Carvello, K. J. Williams, J. Davies, A. Spinelli, A. M. Mehta, J. H. Warusavitarne
    Colorectal Disease.2025;[Epub]     CrossRef
  • Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease—A Prospective Multicenter Cohort Study
    Mirabella Zhao, Lone Larsen, Anders Dige, Anja Poulsen, Bobby Lo, Mohamed Attauabi, Pernille Dige Ovesen, Mads Damsgaard Wewer, Dagmar Christiansen, Christian Lodberg Hvas, Andreas Munk Petersen, Flemming Bendtsen, Jakob Seidelin, Johan Burisch
    Journal of Crohn's and Colitis.2025;[Epub]     CrossRef
  • The Importance of Nutriepigenetics in Older Adults with Inflammatory Bowel Disease
    Ana-Gabriela Prada, Costina Daniela Gîță, Sandra Monica Gîdei, Doina Istratescu, Tudor Stroie, Sorina Maria Aurelian, Gabriel Ioan Prada, Ovidiu Nicolae Penes, Anca Lucia Pop, Mihai Mircea Diculescu
    Nutrients.2025; 17(4): 620.     CrossRef
  • Relationship between smoking status and ulcerative colitis: a meta-analysis based on a case–control study
    Yong Mi, Yue Tan, Yangyang Yu, Dawei An, Rigen Mo, Shenghua Shi, Minhui Li
    Scientific Reports.2025;[Epub]     CrossRef
  • Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately‐to‐Severely Active Crohn's Disease
    Anita Moein, Jakob Ribbing, Moustafa M. A. Ibrahim, Wenhui Zhang, Nastya Kassir
    The Journal of Clinical Pharmacology.2025; 65(10): 1208.     CrossRef
  • The impact of smoking on the intestinal microbiota: From pathogenesis to modern approaches to risk reduction
    T. Yu. Demidova, T. T. Mayarbieva, V. E. Bairova
    FOCUS. Endocrinology.2025; 6(3): 77.     CrossRef
  • Comparative effects of alternate tobacco products and traditional tobacco smoking on various organ/systems: A guide to regulators and health policy makers
    Saheed Olanrewaju Afolabi, Solomon Olagoke Olaoye, Amase Nyamgee, Anoka Ayembe Njan
    Toxicology Reports.2025; 15: 102100.     CrossRef
  • Prevalence of Anti-Anisakis simplex Antibodies in a Cohort of Patients with Inflammatory Bowel Disease in Norway
    María P. de la Hoz-Martín, Juan González-Fernández, Juan Carlos Andreu-Ballester, Marte L. Hoivik, Petr Ricanek, Torunn Bruland, Arne K. Sandvik, Carmen Cuéllar, Ignacio Catalán-Serra
    Pathogens.2025; 14(8): 769.     CrossRef
  • Examination of the TPMT and NUDT15*3 Variants to Predict the Response to Thiopurines in an Italian Cohort of Patients with Inflammatory Bowel Disease
    Francesca Tavano, Orazio Palmieri, Maria Latiano, Domenica Gioffreda, Tiziana Latiano, Maria Guerra, Giuseppina Martino, Maria Rosa Valvano, Fabrizio Bossa, Francesco Perri, Anna Latiano
    International Journal of Molecular Sciences.2025; 26(16): 7860.     CrossRef
  • Ustekinumab in Ulcerative Colitis: A Real-Life Effectiveness Study Across Multiple Belgian Centers (SULTAN)
    Tom Holvoet, Marie Truyens, Catherine Reenaers, Filip Baert, Stijn Vanden Branden, Anneline Cremer, Lieven Pouillon, Pieter Dewint, Wouter Van Moerkercke, Jean-François Rahier, Liv Vandermeulen, Jurgen Van Dongen, Harald Peeters, Guy Lambrecht, Anne Vijve
    Journal of Clinical Medicine.2025; 14(18): 6506.     CrossRef
  • Arrhythmogenic Implications of Inflammatory Bowel Disease: Its Mechanisms and Treatment Effects
    Enayat S Almasri, Tabish W Siddiqui, Rama M Almasri, Gizalla Abdulla, Angela A Benoj, Gayathri Pradeep, Mais O Abu-Sa'da, Ahmad Alaboud , Rand N Fatayerji, Raqshan W Siddiqui
    Cureus.2025;[Epub]     CrossRef
  • Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus
    Shubha Bhat, Ruishen Lyu, Mitali Agarwal, Michelle Becker, Richard Bloomfeld, David H Bruining, Benjamin L Cohen, Marina Ivanov, Jonathan A Leighton, Alyssa P Stewart, Lindsay Trocke, Stacy S Tse, Ryan C Ungaro, Byron P Vaughn, Miguel Regueiro, Erick Sokn
    Inflammatory Bowel Diseases.2024; 30(6): 950.     CrossRef
  • Duration of smoking cessation in patients with inflammatory bowel disease
    Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Federico Bertoletti, Antonio Giordano, Alberto López-Faba, Esther García-Planella
    Gastroenterología y Hepatología.2024; 47(6): 591.     CrossRef
  • Role of Environmental Risk Factors in the Etiology of Inflammatory Bowel Diseases: A Multicenter Study
    Cemile Cansu Alperen, Barıs Soydas, Ender Serin, Mustafa Erbayrak, Nurten Akyurek Savas, Gulhan Kanat Unler, Cenk Emre Meral, Ugur Toprak, Ahmet Sedat Boyacioglu, Ulku Dagli
    Digestive Diseases and Sciences.2024; 69(8): 2927.     CrossRef
  • Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
    Rocío Ferreiro‐Iglesias, Sol Porto Silva, Sandra Marín, María José Casanova, Míriam Mañosa, Carlos González‐Muñoza, Ruth de Francisco, Berta Caballol, Lara Arias, Marta Piqueras, Yamile Zabana, Montserrat Rivero, Xavier Calvet, Francisco Mesonero, Pilar V
    Alimentary Pharmacology & Therapeutics.2024; 60(5): 604.     CrossRef
  • Akkermansia muciniphila and Parabacteroides distasonis as prognostic markers for relapse in ulcerative colitis patients
    Ana Mendes-Frias, Marta Moreira, Maria C. Vieira, Joana Gaifem, Patrício Costa, Luís Lopes, Ricardo Silvestre
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Duration of smoking cessation in patients with inflammatory bowel disease
    Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Federico Bertoletti, Antonio Giordano, Alberto López-Faba, Esther García-Planella
    Gastroenterología y Hepatología (English Edition).2024; 47(6): 591.     CrossRef
  • Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010–2019
    Ryan A. Jasper, Po‐Hung Chen, Reeha Patel, Shelly Joseph, Steven D. Miller, Susan Hutfless
    JGH Open.2023; 7(4): 291.     CrossRef
  • Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
    Jiryeon Jang, Sehoon Jeong
    BioChip Journal.2023; 17(4): 403.     CrossRef
  • High-Dimensional DNA Methylation Mediates the Effect of Smoking on Crohn’s Disease
    Tingting Wang, Pingtian Xia, Ping Su
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Clinical profile, course and outcomes of adults with inflammatory bowel disease over a decade: a single center experience
    Reham Saleh Aljohani, Ali Alaklabi, Yumna Mohammed Alsitary, Majd Abdulrahman bin Khunayn, Shahd Omar Hijazi, Rema Ibraheem Alshagary, Rajkumar Rajendram
    Annals of Saudi Medicine.2022; 42(6): 397.     CrossRef
  • 19,334 View
  • 224 Download
  • 24 Web of Science
  • 26 Crossref
Close layer
Intest Res : Intestinal Research
© Korean Association for the Study of Intestinal Diseases.
Close layer
TOP